Literature DB >> 28702893

Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis.

Justin G Trogdon1, Donatus U Ekwueme2, Diana Poehler3, Cheryll C Thomas2, Katherine Reeder-Hayes4, Benjamin T Allaire3.   

Abstract

BACKGROUND: Younger women (aged 18-44 years) diagnosed with breast cancer often face more aggressive tumors, higher treatment intensity, and lower survival rates than older women. In this study, we estimated incident breast cancer costs by stage at diagnosis and by race for younger women enrolled in Medicaid.
METHODS: We analyzed cancer registry data linked to Medicaid claims in North Carolina from 2003 to 2008. We used Surveillance, Epidemiology, and End Results (SEER) Summary 2000 definitions for cancer stage. We split breast cancer patients into two cohorts: a younger and older group aged 18-44 and 45-64 years, respectively. We conducted a many-to-one match between patients with and without breast cancer using age, county, race, and Charlson Comorbidity Index. We calculated mean excess total cost of care between breast cancer and non-breast cancer patients.
RESULTS: At diagnosis, younger women had a higher proportion of regional cancers than older women (49 vs. 42%) and lower proportions of localized cancers (44 vs. 50%) and distant cancers (7 vs. 9%). The excess costs of breast cancer (all stages) for younger and older women at 6 months after diagnosis were $37,114 [95% confidence interval (CI) = $35,769-38,459] and $28,026 (95% CI = $27,223-28,829), respectively. In the 6 months after diagnosis, the estimated excess cost was significantly higher to treat localized and regional cancer among younger women than among older women. There were no statistically significant differences in excess costs of breast cancer by race, but differences in treatment modality were present among younger Medicaid beneficiaries.
CONCLUSIONS: Younger breast cancer patients not only had a higher prevalence of late-stage cancer than older women, but also had higher within-stage excess costs.

Entities:  

Keywords:  Breast cancer; Medicaid; Medical care costs; Younger women

Mesh:

Year:  2017        PMID: 28702893      PMCID: PMC6081748          DOI: 10.1007/s10549-017-4386-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  36 in total

Review 1.  Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review.

Authors:  Jessica Howard-Anderson; Patricia A Ganz; Julienne E Bower; Annette L Stanton
Journal:  J Natl Cancer Inst       Date:  2012-01-23       Impact factor: 13.506

2.  Big data for population-based cancer research: the integrated cancer information and surveillance system.

Authors:  Anne-Marie Meyer; Andrew F Olshan; Laura Green; Adrian Meyer; Stephanie B Wheeler; Ethan Basch; William R Carpenter
Journal:  N C Med J       Date:  2014 Jul-Aug

3.  Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.

Authors:  Katherine E Reeder-Hayes; Anne Marie Meyer; Stacie B Dusetzina; Huan Liu; Stephanie B Wheeler
Journal:  Breast Cancer Res Treat       Date:  2014-05-01       Impact factor: 4.872

4.  Medicaid status and stage at diagnosis of cervical cancer.

Authors:  Cynthia D O'Malley; Sarah J Shema; Lisa S Clarke; Christina A Clarke; Carin I Perkins
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

5.  Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.

Authors:  Debra E Irwin; Anthony Masaquel; Stephen Johnston; Brian Barnett
Journal:  J Med Econ       Date:  2016-06-07       Impact factor: 2.448

6.  Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service.

Authors:  Helen Blumen; Kathryn Fitch; Vincent Polkus
Journal:  Am Health Drug Benefits       Date:  2016-02

7.  Productivity Costs Associated With Breast Cancer Among Survivors Aged 18-44 Years.

Authors:  Donatus U Ekwueme; Justin G Trogdon; Olga A Khavjou; Gery P Guy
Journal:  Am J Prev Med       Date:  2016-02       Impact factor: 5.043

8.  Breast Cancer in Young Women: Health State Utility Impacts by Race/Ethnicity.

Authors:  Justin G Trogdon; Donatus U Ekwueme; Linda Chamiec-Case; Gery P Guy
Journal:  Am J Prev Med       Date:  2016-02       Impact factor: 5.043

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

10.  Race/ethnicity and socio-economic differences in breast cancer surgery outcomes.

Authors:  Tomi F Akinyemiju; Neomi Vin-Raviv; Daniel Chavez-Yenter; Xueyan Zhao; Henna Budhwani
Journal:  Cancer Epidemiol       Date:  2015-07-29       Impact factor: 2.984

View more
  1 in total

1.  Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.

Authors:  Anagha Gogate; Stephanie B Wheeler; Katherine E Reeder-Hayes; Donatus U Ekwueme; Temeika L Fairley; Sarah Drier; Justin G Trogdon
Journal:  JNCI Cancer Spectr       Date:  2021-07-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.